We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Multiple Myeloma Mouse Model Should Advance Drug Development Efforts

By LabMedica International staff writers
Posted on 18 May 2016
Print article
Image: A photomicrograph showing multiple myeloma cells in the bone marrow (Photo courtesy of the University of Miami School of Medicine).
Image: A photomicrograph showing multiple myeloma cells in the bone marrow (Photo courtesy of the University of Miami School of Medicine).
A recently developed multiple myeloma mouse model is expected to aid in understanding the pathology of the disease and serve as a platform for preclinical testing of potential therapeutic agents.

Investigators at the University of Miami School of Medicine (FL, USA) created the model by crossing two lines of genetically engineered mice. The first line (Mef−/−) lacked the gene for the transcription factor Mef (Elf4), which is known to both promote and suppress the formation of cancers. The second line (Rad50s) contained a mutation in a component of a sensor of DNA damage and regulator of DNA damage response pathways.

The investigators reported in the March 10, 2016, online edition of the journal Scientific Reports that about 70% of the hybrid Mef−/−Rad50s/s mice died from multiple myeloma or other plasma cell cancers.

These mice initially showed an abnormal plasma cell proliferation and monoclonal protein production, and then developed anemia and a decreased bone mineral density. Tumor cells could be serially transplanted. Genome mapping and whole exome sequencing revealed that the pathogenesis of plasma cell cancers in these mice was not linked to activation of a specific oncogene, or inactivation of a specific tumor suppressor (except Mef).

"Multiple myeloma is the second most common hematologic malignancy in the U.S. and it is a very complex disease," said senior author Dr. Stephen D. Nimer, professor of medicine, biochemistry, and molecular biology at the University of Miami School of Medicine. "So far, there have not been animal models of malignant plasma-cell diseases that allow us to study their stepwise progression and fully understand the complex cellular mechanisms. Now that we have a proper model of the disease, we will be able to more effectively study multiple myeloma as well as potential treatments."

"Although outcomes for multiple myeloma patients have greatly improved, it remains an incurable disease, despite the availability of newer treatments," said Dr. Nimer. "Several animal models of multiple myeloma have been reported, including models of human myeloma cells. However, these models imperfectly mimic the human disease. Developing more-reliable and accurate animal models that help us better understand myeloma and test new treatments will take us to the next level on the long and challenging road to a cure."

Related Links:
University of Miami School of Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.